Literature DB >> 21103440

Emerging and novel therapies for hepatitis C.

Ira M Jacobson1.   

Abstract

Year:  2010        PMID: 21103440      PMCID: PMC2978411     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


× No keyword cloud information.
  4 in total

1.  Telaprevir for previously treated chronic HCV infection.

Authors:  John G McHutchison; Michael P Manns; Andrew J Muir; Norah A Terrault; Ira M Jacobson; Nezam H Afdhal; E Jenny Heathcote; Stefan Zeuzem; Hendrik W Reesink; Jyotsna Garg; Mohammad Bsharat; Shelley George; Robert S Kauffman; Nathalie Adda; Adrian M Di Bisceglie
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

2.  Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.

Authors:  Paul Y Kwo; Eric J Lawitz; Jonathan McCone; Eugene R Schiff; John M Vierling; David Pound; Mitchell N Davis; Joseph S Galati; Stuart C Gordon; Natarajan Ravendhran; Lorenzo Rossaro; Frank H Anderson; Ira M Jacobson; Raymond Rubin; Kenneth Koury; Lisa D Pedicone; Clifford A Brass; Eirum Chaudhri; Janice K Albrecht
Journal:  Lancet       Date:  2010-08-06       Impact factor: 79.321

3.  Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.

Authors:  John G McHutchison; Gregory T Everson; Stuart C Gordon; Ira M Jacobson; Mark Sulkowski; Robert Kauffman; Lindsay McNair; John Alam; Andrew J Muir
Journal:  N Engl J Med       Date:  2009-04-30       Impact factor: 91.245

4.  Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.

Authors:  Christophe Hézode; Nicole Forestier; Geoffrey Dusheiko; Peter Ferenci; Stanislas Pol; Tobias Goeser; Jean-Pierre Bronowicki; Marc Bourlière; Shahin Gharakhanian; Leif Bengtsson; Lindsay McNair; Shelley George; Tara Kieffer; Ann Kwong; Robert S Kauffman; John Alam; Jean-Michel Pawlotsky; Stefan Zeuzem
Journal:  N Engl J Med       Date:  2009-04-30       Impact factor: 91.245

  4 in total
  1 in total

1.  Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis.

Authors:  Yuan Kong; Xiaoping Wang; Yushu Shang; Paul M Schroder; Wenhua Liang; Xiaoting Ling; Zhiyong Guo; Xiaoshun He
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.